Charles River Laboratories International, Inc. — Q1 2012 Form 10-Q
Business context and reporting period
The filing reports the unaudited quarter ended March 31, 2012, compared with the three months ended March 26, 2011. Charles River provides research models and related services, and outsourced preclinical services, to pharmaceutical, biotechnology, academic, hospital, and government customers. It reports two segments: Research Models and Services (RMS) and Preclinical Services (PCS).
Key financial results
| Metric | Q1 2012 | Prior comparable quarter |
|---|---|---|
| Net sales | $286.0 million | $285.8 million |
| Operating income / margin | $43.7 million / 15.3% | $42.3 million / 14.8% |
| Net income attributable to common shareholders | $26.4 million | $31.3 million |
| Diluted EPS | $0.54 | $0.57 |
| Cash from operating activities | $25.3 million | $21.4 million |
| Capital expenditures | $14.1 million | $6.8 million |
Gross margin improved to 36.4% from 35.9%. Product sales rose to $126.2 million from $121.4 million, while service sales declined to $159.8 million from $164.4 million. Interest expense was $8.4 million, down from $10.0 million. Income tax expense was $8.7 million versus a $2.7 million tax benefit in the prior quarter; the prior-period benefit included an $11.1 million benefit related to the Phase I clinical business disposition.
RMS sales increased 5.6% to $183.2 million; its operating margin improved to 32.5% from 29.8%. PCS sales fell 8.6% to $102.8 million, and its operating margin decreased to 4.1% from 8.3%, reflecting sales mix, lower biopharmaceutical services sales, and reduced profitability in that business.
Financial position and liquidity
At March 31, 2012, cash and cash equivalents were $61.0 million, compared with $68.9 million at year-end 2011; marketable securities were $6.1 million. Total debt was approximately $704.3 million, including $350.0 million principal on 2.25% convertible notes due June 2013. The company reported compliance with its credit agreement covenants and had a $350 million revolving facility, of which $39 million was drawn; letters of credit totaled $4.3 million.
Operating cash flow was $25.3 million. Investing activities used $3.3 million and financing activities used $30.6 million, including $46.6 million of debt repayments and $15.2 million for treasury stock purchases. Cash declined by $7.9 million during the quarter. Management expects 2012 capital expenditures of approximately $50 million. Cash and marketable securities held by non-U.S. subsidiaries are generally retained to fund foreign operations and are not expected to be repatriated substantially tax-free.
Material changes, outlook, and risks
- Consolidated sales were nearly flat as RMS growth was largely offset by lower PCS sales and unfavorable currency translation. Management cited cost savings and higher RMS sales as contributors to better consolidated gross and operating margins.
- Management described customer demand as uncertain amid measured R&D spending, delayed customer decisions, pricing pressure and excess contract-research capacity, industry consolidation, and reduced biotechnology funding. It sees potential longer-term support from strategic outsourcing but said timing is difficult to predict.
- Management’s priorities include margin improvement, free cash flow, disciplined investment in growth areas, and shareholder returns. The filing gives a capital-expenditure outlook but no specific full-year revenue or earnings guidance.
- The company intends to address the June 2013 convertible-note maturity using cash, operating cash flow, credit capacity, and potentially other financing alternatives. The filing notes no conversion triggers had been met at quarter-end.
- A putative California employee class action was filed in January 2012; management intends to defend it, and the possible loss range could not be estimated. The company also remains the guarantor of a lease related to the disposed Phase I business; remaining lease payments were $14.4 million, with a recorded guarantee liability.
- Tax authorities are auditing or disputing certain tax matters, including Canadian research-credit claims; management does not expect resolution to materially affect financial position or results. The company recorded a $0.7 million realized loss on the sale of auction-rate securities.
- Management reported effective disclosure controls and no material changes to internal control over financial reporting. It reported no material changes to the risk factors in its 2011 Form 10-K.
Important facts for investors to verify
- Whether PCS sales and margins stabilize, particularly in biopharmaceutical services, and whether RMS growth continues.
- Progress toward the $50 million 2012 capital-expenditure plan and management’s free-cash-flow objectives.
- Funding plans and refinancing or repayment capacity for the $350 million convertible notes due June 2013.
- Customer spending, outsourcing demand, pricing pressure, and foreign-exchange effects on sales and cash generation.
- Developments in the California class action, tax disputes, and the Phase I facility lease guarantee.